- Home
- TALK vs IMTX Comparison
TALK vs IMTX Comparison
Compare TALK & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TALK
- IMTX
- Stock Information
- Founded
- TALK 2012
- IMTX N/A
- Country
- TALK United States
- IMTX Germany
- Employees
- TALK N/A
- IMTX N/A
- Industry
- TALK Medical/Nursing Services
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TALK Health Care
- IMTX Health Care
- Exchange
- TALK Nasdaq
- IMTX Nasdaq
- Market Cap
- TALK 486.1M
- IMTX 579.8M
- IPO Year
- TALK N/A
- IMTX N/A
- Fundamental
- Price
- TALK $3.25
- IMTX $5.78
- Analyst Decision
- TALK Buy
- IMTX Strong Buy
- Analyst Count
- TALK 6
- IMTX 4
- Target Price
- TALK $4.50
- IMTX $14.67
- AVG Volume (30 Days)
- TALK 2.0M
- IMTX 669.0K
- Earning Date
- TALK 05-06-2025
- IMTX 05-13-2025
- Dividend Yield
- TALK N/A
- IMTX N/A
- EPS Growth
- TALK N/A
- IMTX N/A
- EPS
- TALK 0.02
- IMTX N/A
- Revenue
- TALK $194,359,000.00
- IMTX $155,801,989.00
- Revenue This Year
- TALK $22.39
- IMTX N/A
- Revenue Next Year
- TALK $20.33
- IMTX $5.61
- P/E Ratio
- TALK $187.76
- IMTX N/A
- Revenue Growth
- TALK 19.88
- IMTX 93.56
- 52 Week Low
- TALK $1.60
- IMTX $3.30
- 52 Week High
- TALK $4.36
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- TALK 57.66
- IMTX 63.06
- Support Level
- TALK $2.70
- IMTX $4.93
- Resistance Level
- TALK $3.43
- IMTX $6.16
- Average True Range (ATR)
- TALK 0.15
- IMTX 0.40
- MACD
- TALK 0.03
- IMTX 0.07
- Stochastic Oscillator
- TALK 66.27
- IMTX 67.84
About TALK Talkspace Inc.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.